Across TCGA pan-cancer cohorts, FAM181B Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FAM181B data layer compared with 26 for mass-spec protein.
The strongest signal is observed in brain lower grade glioma (LGG), where higher FAM181B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM181B expression acts as an unfavorable survival marker.
LGG are the cancer types where FAM181B Mutation most reproducibly stratifies survival.